Moolec Science SA Ordinary Shares (MLEC) - Net Assets
Based on the latest financial reports, Moolec Science SA Ordinary Shares (MLEC) has net assets worth $2.80 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.38 Million) and total liabilities ($28.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MLEC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.80 Million |
| % of Total Assets | 8.91% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 673.21 |
Moolec Science SA Ordinary Shares - Net Assets Trend (2021–2025)
This chart illustrates how Moolec Science SA Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Also explore Moolec Science SA Ordinary Shares asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Moolec Science SA Ordinary Shares (2021–2025)
The table below shows the annual net assets of Moolec Science SA Ordinary Shares from 2021 to 2025. For live valuation and market cap data, see Moolec Science SA Ordinary Shares (MLEC) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-82.87 Million | -1315.91% |
| 2024-06-30 | $6.82 Million | -32.56% |
| 2023-06-30 | $10.11 Million | +529.91% |
| 2022-06-30 | $1.60 Million | -98.80% |
| 2021-06-30 | $134.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Moolec Science SA Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10948986800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.09 Million | % |
| Other Comprehensive Income | $3.93 Million | % |
| Other Components | $39.32 Million | % |
| Total Equity | $-65.97 Million | 100.00% |
Moolec Science SA Ordinary Shares Competitors by Market Cap
The table below lists competitors of Moolec Science SA Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Solteq PLC
HE:SOLTEQ
|
$6.55 Million |
|
ICDS Limited
NSE:ICDSLTD
|
$6.55 Million |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
$6.56 Million |
|
Moho Resources Ltd
AU:MOH
|
$6.56 Million |
|
Kontigo Care AB
ST:KONT
|
$6.54 Million |
|
ARIP Public Company Limited
BK:ARIP
|
$6.54 Million |
|
Gold Pacific Co. Ltd
KQ:038530
|
$6.53 Million |
|
Victrex plc
LSE:VCT
|
$6.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Moolec Science SA Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,815,760 to -65,971,082, a change of -72,786,842 (-1067.9%).
- Net loss of 111,460,708 reduced equity.
- Share repurchases of 926,899 reduced equity.
- Other comprehensive income increased equity by 3,808,399.
- Other factors increased equity by 35,792,366.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-111.46 Million | -168.95% |
| Share Repurchases | $926.90K | -1.41% |
| Other Comprehensive Income | $3.81 Million | +5.77% |
| Other Changes | $35.79 Million | +54.25% |
| Total Change | $- | -1067.92% |
Book Value vs Market Value Analysis
This analysis compares Moolec Science SA Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $115.79 | $10.37 | x |
| 2022-06-30 | $0.64 | $10.37 | x |
| 2023-06-30 | $4.40 | $10.37 | x |
| 2024-06-30 | $2.66 | $10.37 | x |
| 2025-06-30 | $-153.11 | $10.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Moolec Science SA Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.41%
- • Asset Turnover: 1.63x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-180.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -0.01% | 0.00% | 0.00x | 1.03x | $-13.42 Million |
| 2022 | -282.17% | 0.00% | 0.00x | 3.55x | $-4.69 Million |
| 2023 | -512.46% | -5722.22% | 0.04x | 2.38x | $-52.80 Million |
| 2024 | -107.28% | -129.99% | 0.16x | 5.10x | $-7.99 Million |
| 2025 | 0.00% | -33.41% | 1.63x | 0.00x | $-104.86 Million |
Industry Comparison
This section compares Moolec Science SA Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Moolec Science SA Ordinary Shares (MLEC) | $2.80 Million | -0.01% | 10.22x | $6.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Moolec Science SA Ordinary Shares
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans… Read more